WO2005021541A3 - Process for the production of polymorphs of rosiglitazone maleate - Google Patents

Process for the production of polymorphs of rosiglitazone maleate Download PDF

Info

Publication number
WO2005021541A3
WO2005021541A3 PCT/GB2004/003519 GB2004003519W WO2005021541A3 WO 2005021541 A3 WO2005021541 A3 WO 2005021541A3 GB 2004003519 W GB2004003519 W GB 2004003519W WO 2005021541 A3 WO2005021541 A3 WO 2005021541A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphs
production
rosiglitazone maleate
rosiglitazone
maleate
Prior art date
Application number
PCT/GB2004/003519
Other languages
French (fr)
Other versions
WO2005021541A2 (en
Inventor
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Manjinder Singh Phull
Dilip Ramdas Birari
Original Assignee
Cipla Ltd
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Manjinder Singh Phull
Dilip Ramdas Birari
Wain Christopher Paul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manjinder Singh Phull, Dilip Ramdas Birari, Wain Christopher Paul filed Critical Cipla Ltd
Priority to CA002536784A priority Critical patent/CA2536784A1/en
Priority to DE112004001572T priority patent/DE112004001572T5/en
Priority to US10/569,439 priority patent/US7678916B2/en
Priority to KR1020067004005A priority patent/KR101145433B1/en
Priority to AU2004268816A priority patent/AU2004268816B2/en
Priority to GB0606312A priority patent/GB2421504B/en
Publication of WO2005021541A2 publication Critical patent/WO2005021541A2/en
Publication of WO2005021541A3 publication Critical patent/WO2005021541A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to processes for the preparation of rosiglitazone, rosiglitazone prepared thereby and pharmaceutical compositions and therapeutic uses thereof, and methods of treatment employing the same.
PCT/GB2004/003519 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate WO2005021541A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002536784A CA2536784A1 (en) 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate
DE112004001572T DE112004001572T5 (en) 2003-08-29 2004-08-13 method
US10/569,439 US7678916B2 (en) 2003-08-29 2004-08-13 Process
KR1020067004005A KR101145433B1 (en) 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate
AU2004268816A AU2004268816B2 (en) 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate
GB0606312A GB2421504B (en) 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0320304.9 2003-08-29
GB0320304A GB2405403A (en) 2003-08-29 2003-08-29 Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base

Publications (2)

Publication Number Publication Date
WO2005021541A2 WO2005021541A2 (en) 2005-03-10
WO2005021541A3 true WO2005021541A3 (en) 2005-05-06

Family

ID=28686590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003519 WO2005021541A2 (en) 2003-08-29 2004-08-13 Process for the production of polymorphs of rosiglitazone maleate

Country Status (9)

Country Link
US (1) US7678916B2 (en)
KR (1) KR101145433B1 (en)
AU (1) AU2004268816B2 (en)
CA (1) CA2536784A1 (en)
DE (1) DE112004001572T5 (en)
GB (2) GB2405403A (en)
RU (1) RU2342385C2 (en)
TR (1) TR200601379T1 (en)
WO (1) WO2005021541A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CZ297266B6 (en) * 2004-09-10 2006-10-11 Zentiva, A. S. Process for preparing rosiglitazone
WO2009104200A1 (en) * 2008-02-21 2009-08-27 Biocon Limited A method for preparation of thiazolidinedione derivatives
EP2184055A1 (en) * 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
WO1999031095A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
WO1999031093A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
WO1999031094A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt
WO2000064896A1 (en) * 1999-04-23 2000-11-02 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
WO2000064893A2 (en) * 1999-04-23 2000-11-02 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
WO2000064892A2 (en) * 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
WO2002026737A1 (en) * 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
EP1219620A1 (en) * 1997-11-04 2002-07-03 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
WO2004085435A1 (en) * 2003-03-28 2004-10-07 Glaxo Group Limited Process for preparing a polymorph of rosiglitazone maleate
EP1468997A2 (en) * 2003-04-18 2004-10-20 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602291B1 (en) * 1999-04-05 2003-08-05 Raymedica, Inc. Prosthetic spinal disc nucleus having a shape change characteristic
US7060100B2 (en) * 1999-10-08 2006-06-13 Ferree Bret A Artificial disc and joint replacements with modular cushioning components
US6733533B1 (en) * 2002-11-19 2004-05-11 Zimmer Technology, Inc. Artificial spinal disc
US6893465B2 (en) * 2003-03-31 2005-05-17 Shi, Tain-Yew Vividly simulated prosthetic intervertebral disc

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
EP1219620A1 (en) * 1997-11-04 2002-07-03 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
WO1999031093A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
WO1999031094A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt
WO1999031095A1 (en) * 1997-12-16 1999-06-24 Smithkline Beecham Plc 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
WO2000064896A1 (en) * 1999-04-23 2000-11-02 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
WO2000064893A2 (en) * 1999-04-23 2000-11-02 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
WO2000064892A2 (en) * 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1277753A1 (en) * 1999-04-23 2003-01-22 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
EP1284268A1 (en) * 1999-04-23 2003-02-19 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
WO2002026737A1 (en) * 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
WO2004085435A1 (en) * 2003-03-28 2004-10-07 Glaxo Group Limited Process for preparing a polymorph of rosiglitazone maleate
EP1468997A2 (en) * 2003-04-18 2004-10-20 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate

Also Published As

Publication number Publication date
RU2006110040A (en) 2007-10-10
AU2004268816A1 (en) 2005-03-10
KR101145433B1 (en) 2012-05-16
US20060264639A1 (en) 2006-11-23
GB0606312D0 (en) 2006-05-10
GB2421504B (en) 2008-12-03
AU2004268816B2 (en) 2011-04-14
WO2005021541A2 (en) 2005-03-10
DE112004001572T5 (en) 2006-07-06
GB2421504A (en) 2006-06-28
GB0320304D0 (en) 2003-10-01
GB2405403A (en) 2005-03-02
TR200601379T1 (en) 2007-01-22
US7678916B2 (en) 2010-03-16
KR20070027483A (en) 2007-03-09
RU2342385C2 (en) 2008-12-27
CA2536784A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
WO2003000699A8 (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain
HUP0401213A3 (en) Compounds effecting glucokinase, process for their preparation and their use for production of pharmaceutical compositions
WO2006055511A3 (en) Stable tablet formulation of tetrahydrobiopterin
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2005046603A3 (en) Pyridine compounds
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2004112719A8 (en) Chemical compounds
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004105781A3 (en) Stabilized pharmaceutical peptide compositions
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2003051362A3 (en) Polymorphs of clopidogrel hydrogensulfate
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
WO2006023843A3 (en) Novel heterocycles
WO2004099132A3 (en) Process for the preparation of trans-isomers of diphenylazetidinone derivatives
WO2004106322A3 (en) Polymorphs of aripiprazole
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2002076438A3 (en) Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
WO2005055943A3 (en) Vinorelbine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004268816

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2536784

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067004005

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1120040015723

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2004268816

Country of ref document: AU

Date of ref document: 20040813

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004268816

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/01379

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 346/MUMNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 0606312.7

Country of ref document: GB

Ref document number: 2006110040

Country of ref document: RU

Ref document number: 0606312

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 2006264639

Country of ref document: US

Ref document number: 10569439

Country of ref document: US

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10569439

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020067004005

Country of ref document: KR